News
S-ICD ‘noninferior’ to transvenous-lead ICD in head-to-head PRAETORIAN trial
Younger patients without heart failure “are the kind of patient who you would probably lean very strongly toward for an S-ICD rather than a...
News
VICTORIA: Vericiguat seen as novel success in tough-to-treat, high-risk heart failure
The relative risk reduction was modest, but experts say the benefit in absolute terms was remarkable for already well-treated patients.
News
Societies dig in to EXCEL trial controversy
EACTS-ESC calls for evidence review and development of updated recommendations for left-main disease “as a matter of urgency.”
News
FDA panel rejects vernakalant bid for AFib cardioversion indication
Eleven years after the first attempt of the antiarrhythmic agent, the FDA panel voted resoundingly against approval.
News
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.